...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Not adding up!

Forget about Zenith Market valuation for now. , what does Newsora see in data and  current trials for Zen3694, are they thinking they are getting a deal of the century or just taking a long shot chance on the chance FDA   drug registration in the next 2 to 4 years .  That being said , Why have not 1 BP step up to take a larger partnership pice of Zenith other than just a small clinical collaboration...... 

Share
New Message
Please login to post a reply